<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Biased-Agonism-5ht2a on 生物经济</title><link>https://cn.bioecon.ru/technologies/biased-agonism-5ht2a/</link><description>Recent content in Biased-Agonism-5ht2a on 生物经济</description><generator>Hugo</generator><language>zh-CN</language><lastBuildDate>Sat, 04 Jul 2026 22:52:18 +0700</lastBuildDate><atom:link href="https://cn.bioecon.ru/technologies/biased-agonism-5ht2a/index.xml" rel="self" type="application/rss+xml"/><item><title>致幻剂医学与神经精神生物制剂</title><link>https://cn.bioecon.ru/technology/psychedelic-medicine-neuropsychiatric-biologics/</link><pubDate>Sat, 04 Jul 2026 00:00:00 +0000</pubDate><guid>https://cn.bioecon.ru/technology/psychedelic-medicine-neuropsychiatric-biologics/</guid><description>精神活性化合物疗法（裸盖菇素、MDMA、5-甲氧基-DMT）及通过血清素5-HT2A受体信号通路触发快速突触发生的新一代非致幻性神经可塑性药物，针对难治性抑郁症与创伤后应激障碍——这是一个在2026年既有真实临床突破、也有备受关注的FDA监管挫折的领域。</description></item></channel></rss>